Seizure News and Research

Latest Seizure News and Research

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

Biogen Idec announced today that the European Commission (EC) has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event.

7 Jun 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Biogen Idec today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy.

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Topiramate drug can help people lose weight

The drug topiramate can help people lose weight as long as they can tolerate the side effects, according to authors of a new study that reviewed the medical literature. Brazilian researchers will present the results Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Researchers develop new technology to detect neurological symptoms associated with epileptic seizure

Tiny electrodes have been coated with a drug-loaded polymer in an attempt to design an implant capable of detecting a number of neurological symptoms, such as those associated with an epileptic seizure, and treating them simultaneously.

4 Jun 2011

Study shows cognitive impairment is evident in preschool children

A recent study has shown that cognitive impairment is evident early on in preschool children with epilepsy, consistent with results of similar studies in older children.

3 Jun 2011

Insight into beneficial epilepsy treatments for children with autism

Physicians will have a better guide for more effectively managing treatment of children experiencing seizures related to autism with the results of a study by researchers at Arizona State University and the University of Texas-Houston.

3 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

After years of building hope for a treatment, Rochester researchers and clinicians will begin the first controlled clinical trial for Juvenile Batten disease this summer, thanks to $1 million in grants from the Food and Drug Administration and the Batten Disease Support and Research Association.

1 Jun 2011

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.

30 May 2011

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients - estimated to be as many as 1 million in the U.S. - drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

26 May 2011

FDA warns online retailers for illegal tobacco product marketing

The U.S. Food and Drug Administration today announced it issued 11 warning letters last week to online retailers for illegally marketing tobacco products with misleading or unsubstantiated claims or descriptors indicating that they can be used to reduce harm or the risk of tobacco-related disease.

26 May 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Biogen Idec launches educational forum, 'Women in MS'

Biogen Idec today announced the launch of "Women in MS," an educational initiative to address both the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis.

25 May 2011

Study provides insight into effective treatments for autism spectrum disorder, seizures

Roughly 25-35% of individuals with autism eventually develop seizures and many of the remainder have subclinical seizure-like brain activity. However, little is known about which traditional epilepsy treatments and commonly used non-traditional alternative treatments are effective for treating seizures or epilepsy in children and adults with autism spectrum disorder.

25 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

Researcher says a comparison with epilepsy is an appropriate prism to view economics

Since 2008, the U.S. economy has been "seizing" uncontrollably. Now a Tel Aviv University researcher says that a comparison of the multifaceted economic downturn with the uncontrolled spasms of an epileptic is not inappropriate - and may say something about the origins of the disaster.

13 May 2011

Seizure News and Research

Latest Seizure News and Research

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Topiramate drug can help people lose weight

Researchers develop new technology to detect neurological symptoms associated with epileptic seizure

Study shows cognitive impairment is evident in preschool children

Insight into beneficial epilepsy treatments for children with autism

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

FDA warns online retailers for illegal tobacco product marketing

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Biogen Idec launches educational forum, 'Women in MS'

Study provides insight into effective treatments for autism spectrum disorder, seizures

EMA CHMP recommends conditional marketing authorization of FAMPYRA

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Researcher says a comparison with epilepsy is an appropriate prism to view economics

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Seizure News and Research

Latest Seizure News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in